- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
October 10, 2024Michael Collyard and Ronald Schutz Named to Minnesota Lawyer’s Power 30: Business Litigation List
-
October 9, 2024Michael Geibelson Named to Daily Journal’s Top Trade Secrets Lawyers
-
October 8, 2024Robins Kaplan Partners Named Women Worth Watching in Leadership
-
October 20, 2024License Agreement Disputes:
-
October 21, 2024How Much Did We Invest in AI?
-
October 22, 2024Justice for All: Minnesota's Civil Legal Aid and Pro Bono Landscape
-
September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
PTAB Issues Key Decision Over Revolutionary CRISPR Technology, but this Tale is Not Over Yet
February 21, 2017
The gene-editing tool CRISPR is in the process of transforming the life sciences industry. Perhaps not surprisingly with such a revolutionary technology still in its relative infancy, a dispute over patents between universities and research institutes that have been at the forefront of its development, erupted over just who owns some of the foundational IP.
Last week in a closely watched decision, the Patent Trial and Appeal Board (PTAB) ruled in favour of the Broad Institute, a non-profit research organisation affiliated with the Massachusetts Institute of Technology (MIT) and Harvard, in an interference proceeding involving a dozen patents that were challenged by the University of California, University of Vienna and Dr Emmanuelle Charpentier. In this blog Cyrus Morton and Sharon Roberg-Perez of Robins Kaplan LLP look at the implications of the PTAB’s ruling and explain that in a rapidly evolving licensing market, more disputes over CRISPR could be on the horizon. Here’s what they have to say.
Reprinted with permission from the February 21, 2017 issue of iam. © 2017 Globe Business Media Group. Further duplication without permission is prohibited. All rights reserved.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Sharon Roberg-Parez
Former Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.